Abstract
Liquid biopsies represent a paradigm shift in the field of oncology, offering a transformative approach to cancer detection, monitoring, and treatment planning. Unlike traditional tissue biopsies, liquid biopsies provide a comprehensive dynamic, and non-invasive method to analyze tumor-derived biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and exosomes from body fluids. This innovation addresses the limitations of conventional diagnostics, including invasiveness, sampling bias, and the inability to capture tumor heterogeneity. With rapid advancements in technologies such as digital PCR, liquid biopsies and next-generation sequencing (NGS) have become increasingly sensitive, specific, and clinically actionable. Current article delivers an in-depth exploration of the principles, applications, and benefits of liquid biopsies, alongside a critical analysis of their challenges and limitations. By highlighting recent breakthroughs and future directions, we underscore the immense potential of liquid biopsies to revolutionize precision oncology, improve patient outcomes, and redefine the landscape of cancer care.
Keywords: Cancer, ctDNA, Heterogeneity, Liquid Biopsies, Oncology, Tumor